Health Care & Life Sciences » Pharmaceuticals | Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. Cl A
Stock Exchange NASDAQ Stock Market
EPS
$3.99
Market Cap
$2.7 B
Shares Outstanding
24.42 M
Public Float
22.32 M

Profile

Address
2801 Gateway Drive
Irving Texas 75063
United States
Employees -
Website http://www.reatapharma.com
Updated 07/08/2019
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J.

Financials

View All

J. Warren Huff
Chairman, President & Chief Executive Officer
William D. McClellan
Independent Director